Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXSCEL: Exenatide CV Outcomes in T2DM
NCT01144338Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Apr 2017
- Modality
- Peptides
- Countries
- 35
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jun 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01144338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144338.